AKT1 and central nervous system cancer: Silencing MTCH2 disrupted mitochondrial function, caused oxidative damage, impaired cell migration and invasion, inhibited the pro-survival Akt signaling pathway, and heightened sensitivity to temozolomide in glioma cells [33].